Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial (Q42199381)

18 October 2017

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial (English)

1 reference

18 October 2017

phase I clinical trial

0 references

0 references

1 reference

17

Theodore C Pierson

1 reference

18 October 2017

16

John R Mascola

1 reference

18 October 2017

2

Kimberly A Dowd

1 reference

18 October 2017

15

Gary J Nabel

1 reference

18 October 2017

18

Barney S Graham

1 reference

18 October 2017

19

Julie E Ledgerwood

1 reference

18 October 2017

10

Mary E Enama

1 reference

18 October 2017

12

Richard A Koup

1 reference

18 October 2017

13

Richard M Schwartz

1 reference

18 October 2017

8

Uzma N Sarwar

1 reference

18 October 2017

7

Galina Yamshchikov

1 reference

18 October 2017

3

Floreliz H Mendoza

1 reference

18 October 2017

5

Sandra Sitar

1 reference

18 October 2017

1

Lee-Jah Chang

1 reference

18 October 2017

14

Wataru Akahata

1 reference

18 October 2017

6

Sarah H Plummer

1 reference

18 October 2017

Jamie G Saunders

4

1 reference

18 October 2017

Zonghui Hu

series ordinal

9

1 reference

18 October 2017

Robert T Bailer

series ordinal

11

1 reference

18 October 2017

VRC 311 Study Team

series ordinal

20

1 reference

18 October 2017

language of work or name

English

0 references

publication date

14 August 2014

1 reference

18 October 2017

1 reference

18 October 2017

384

1 reference

18 October 2017

2046-2052

1 reference

18 October 2017

9959

1 reference

on focus list of Wikimedia project

18 October 2017

ScienceSource

0 references

cites work

A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Present and future arboviral threats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Chikungunya: a potentially emerging epidemic?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Chikungunya, an epidemic arbovirosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Chikungunya: a bending reality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Tracing the path of Chikungunya virus--evolution and adaptation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Chikungunya fever: an epidemiological review of a re-emerging infectious disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Comparative role of Aedes albopictus and Aedes aegypti in the emergence of Dengue and Chikungunya in central Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Chikungunya: an emerging and spreading arthropod-borne viral disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Epidemiology, clinical manifestations, and diagnosis of Chikungunya fever: lessons learned from the re-emerging epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Emergence and clinical insights into the pathology of Chikungunya virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Infection with chikungunya virus in Italy: an outbreak in a temperate region

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Detection of viral ribonucleic acid and histologic analysis of inflamed synovium in Ross River virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Atypical manifestations of chikungunya infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Chikungunya and the nervous system: what we do and do not know

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Neurological complications of Chikungunya virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Chikungunya virus and prospects for a vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Chimeric alphavirus vaccine candidates for chikungunya

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Effective chikungunya virus-like particle vaccine produced in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

Prophylaxis and therapy for Chikungunya virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961185-5

7 January 2021

10.1016/S0140-6736(14)61185-5

Identifiers

DOI

1 reference

18 October 2017

1 reference